Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Angelini Ventures
BioCentury | Feb 2, 2024
Finance
VC roundup: New funds for TCG and Seroba, rounds for Cour and Aqemia
Plus fresh cash for Halia and Neophore, and a new spinout from venture-backed Cumulus Oncology
BioCentury | Dec 14, 2023
Deals
Dec. 13 Quick Takes: Vertex heads off patent issues with Editas deal
Plus: Pfizer loses $11B in value after 2024 guidance and updates from J&J, Shattuck Labs, Vir, CARsgen, Freya and EvolveImmune
BioCentury | Oct 21, 2022
Deals
Oct. 21 Quick Takes: Newly spun out Biohaven prices upsized follow-on
Plus Singapore’s AUM merging with SPAC, and updates from Angelini and DeepUll
BioCentury | Sep 14, 2022
Emerging Company Profile
Pretzel: modulating the mitochondrial genome
Arch-incubated newco launched Monday with $72.5M and three platforms to tackle mitochondrial diseases
Items per page:
1 - 4 of 4